Latest / Jersey City News Today | 2 Min News | The Daily News Now!
Moderna and Merck’s mRNA Melanoma Breakthrough | Jersey News
Moderna and Merck just dropped a game-changing update on their personalized mRNA melanoma vaccine, which, when combined with Keytruda, slashed the risk of cancer recurrence in high-risk patients. Custom-built for each individual using their tumor’s genetic code, the vaccine trains the immune system to target cancer cells with surgical precision. While not yet FDA approved, the Phase Three trial results—showing clear superiority over Keytruda alone in over 1,100 patients—are a major milestone. Experts predict potential approval by 2027, and researchers are already exploring similar mRNA…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.